

**4D MOLECULAR THERAPEUTICS, INC.**  
**SCIENCE AND TECHNOLOGY COMMITTEE CHARTER**

This Science and Technology Committee Charter (this “Charter”) was adopted by the Board of Directors (the “Board”) of 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), on November 25, 2020, effective upon the consummation of the Company’s initial public offering, and last amended on October 8, 2024.

**I. Purpose**

The purpose of the Science and Technology Committee (the “Committee”) of the Board is to assist the Board’s oversight of the strategic direction of the Company’s science and technology, as well as its research and development activities (both translational and clinical).

In addition to the powers and responsibilities expressly delegated to the Committee in this Charter, the Committee may exercise any other powers and carry out any other responsibilities delegated to it by the Board from time to time consistent with the Company’s bylaws (as in effect from time to time) and applicable law. The powers and responsibilities delegated by the Board to the Committee in this Charter or otherwise shall be exercised and carried out by the Committee as it deems appropriate without requirement of Board approval. While acting within the scope of the powers and responsibilities delegated to it, the Committee shall have and may exercise all the powers and authority of the Board.

**II. Composition**

The Committee shall be composed of at least two (2) directors as determined by the Board. The members of the Committee, including the Chairperson of the Committee (the “Chair”), shall be appointed by the Board. Committee members may be removed from the Committee, with or without cause and with or without prior notice, by the Board. Unless a Chair is designated by the Board, the Committee may designate a Chair by majority vote of the full Committee membership. The members of the Committee will serve until resignation, retirement, or removal by the Board or until their successors shall be appointed.

**III. Meetings, Procedures and Authority**

The Chair (or in his or her absence, a member designated by the Chair) shall preside at each meeting of the Committee and set the agendas for Committee meetings. The Committee shall have the authority to establish its own rules and procedures for notice and conduct of its meetings so long as they are not inconsistent with any provisions of the Company’s bylaws that are applicable to the Committee.

The Committee should meet as often as it determines advisable to fulfill its duties and responsibilities. Meetings of the Committee may be called by the Chair upon notice given at least twenty-four (24) hours prior to the meeting, or upon such shorter notice as shall be approved by the Committee. The Chair shall designate a secretary for each meeting who shall record minutes of all formal actions of the Committee. A majority of the Committee members, present in person or by phone or videoconference, shall constitute a quorum. A majority of the members present

shall decide any questions brought before the Committee, except to the extent otherwise required by the Company's certificate of incorporation or bylaws (each as in effect from time to time). Unless otherwise restricted by the Company's bylaws, any action required or permitted to be taken at any meeting of the Committee may be taken without a meeting if all members of the Committee consent thereto in writing (including by electronic transmission), and such writing (including any electronic transmission) is filed with the minutes of the Committee.

The Committee shall keep regular minutes of any meetings where actions are taken (unless such actions are taken and reported to the Committee's satisfaction in the minutes of the Board meetings). Any such minutes kept by the Committee shall be distributed to each member of the Committee. The Corporate Secretary shall maintain the original signed minutes for filing with the corporate records of the Company. The Chair, or any member of the Committee as requested by the Board, shall report to the Board regarding the activities of the Committee at appropriate times and as otherwise requested by the Chairperson of the Board.

The Committee has the authority to retain any other advisors that the Committee believes to be desirable and appropriate and has the authority to approve related fees and retention terms. The Committee shall have access to internal advisors and other resources within the Company to assist it in carrying out its duties and responsibilities.

#### **IV. Duties and Responsibilities**

1. *Science Matters.* The Committee shall have generalized supervisory responsibilities, along with the Board, for the Company's investments in science and technology. In discharging its responsibilities, the Committee shall:

(a) Review, evaluate and advise the Board on the overall strategy, direction and effectiveness of the Company's technology, as well as its research and development programs (both translational and clinical), and related investments, and on the Company's progress in achieving its long-term technology and strategic research and development (both translational and clinical) goals and objectives.

(b) Monitor and evaluate trends in technologies relevant to the Company's present and future business, and report to the Board and management regarding such technologies for building the Company's technological strength.

(c) Evaluate and advise the Board and management on the soundness, opportunities and risks associated with the products, programs and technologies in which the Company is, or is considering, investing its research and development efforts.

(d) Review and advise the Board on the Company's current and potential internal and external programs and investments in science and technology. For any external programs and investments in products and technologies (e.g., potential licenses, acquisitions, collaborations or equity investments) that require approval by the Board, the Committee may be asked to provide the Board and management with its advice prior to such Board action.

(e) Regularly review and make recommendations to the Board and management with respect to the Company's research and development pipeline.

2. *Committee Self-Evaluation.* The Committee shall, periodically and with input from the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”) if deemed appropriate, perform an evaluation of the performance of the Committee and its members, including a review of the Committee’s compliance with this Charter, and provide any written material with respect to such evaluation to the Board or the Nominating and Corporate Governance Committee, as appropriate, including any recommendations for changes in procedures or policies governing the Committee.
3. *Review of this Charter.* The Committee shall periodically review and reassess this Charter and submit any recommended changes to the Board for its consideration.

**V. Delegation of Duties**

In fulfilling its responsibilities, the Committee has the authority to delegate any or all of its responsibilities to a subcommittee of the Committee.

\* \* \* \* \*